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Background: Angiotensin receptor blockers (ARBs) are reported to provide direct protection to many organs by
controlling inflammation and decreasing oxidant stress. Pioglitazone, an anti-diabetic agent that improves insulin
resistance, was also reported to decrease inflammation and protect against atherosclerosis. This study aimed to
evaluate the utility of combination therapy with both medicines from the viewpoint of anti-inflammatory effects.
Methods: We administered candesartan (12 mg daily) and pioglitazone (15 mg daily) simultaneously for 6 months
to hypertensive patients with type 2 diabetes mellitus (T2DM) and evaluated whether there were improvements in
the serum inflammatory parameters of high-molecular-weight adiponectin (HMW-ADN), plasminogen activator
inhibitor-1 (PAI-1), highly sensitive C-reactive protein (Hs-CRP), vascular cell adhesion molecule-1 (VCAM-1), and
urinary-8-hydroxydeoxyguanosine (U-8-OHdG). We then analyzed the relationship between the degree of
reductions in blood pressure and HbA1c values and improvements in inflammatory factors. Furthermore, we
analyzed the relationship between pulse pressure and the degree of lowering of HbA1c and improvements in
inflammatory factors. Finally, we examined predictive factors in patients who received benefits from the
co-administration of candesartan with pioglitazone from the viewpoint of inflammatory factors.
Results: After 6 months of treatment, in all patients significant improvements from baseline values were observed
in HMW-ADN and PAI-1 but not in VCAM-1, Hs-CRP, and U-8-OHdG. Changes in HbA1c were significantly correlated
with changes in HMW-ADN and PAI-1 in all patients, but changes in blood pressure were not correlated with any
of the parameters examined. Correlation and multilinear regression analyses were performed to determine which
factors could best predict changes in HbA1c. Interestingly, we found a significant positive correlation of pulse
pressure values at baseline with changes in HbA1c.
Conclusions: Our data suggest that the pulse pressure value at baseline is a key predictive factor of changes in
HbA1c. Co-administration of candesartan with pioglitazone, which have anti-inflammatory (changes in HMW-ADN
and PAI-1) effects and protective effects on organs, could be an effective therapeutic strategy for treating
hypertensive patients with type 2 diabetes mellitus.
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pressureBackground
It is well established that hypertension complicated with
T2DM results in an increased incidence of cardiovascular
disease [1]. Hence, to reduce cardiovascular events in pa-
tients with T2DM, treatment of hypertension in addition
to glycemic control is important [2,3]. Angiotensin recep-
tor blockers (ARBs) are regarded as first-line therapy for
hypertensive patients with T2DM. Moreover, a large-scale
clinical trial showed that the use of ARBs prevented the
onset of diabetes mellitus. Recently, ARBs received much
attention in terms of decreasing oxidant stress and con-
trolling inflammation in organs. Previously we reported
that candesartan improved inflammatory parameters
(HMW-ADN and PAI-1) in hypertensive patients with
T2DM of long duration independently of blood pressure
changes [4].
Pioglitazone is a diabetic medicine that improves insu-
lin resistance. That pioglitazone directly reduces the in-
cidence of cardiovascular events and stroke was shown
by the PROactive Study, a large-scale clinical trial [5,6].
The protective action of pioglitazone on organs is thought
to be through an anti-inflammatory action that reduces
oxidant stress similar to ARBs as previously noted [7-10].
Therefore, using medicines such as pioglitazone in con-
junction with an ARB might be useful not only with re-
spect to blood pressure and plasma glucose control but
also from the viewpoint of protection of organs.
Because the prevalence of metabolic syndrome has in-
creased worldwide and the number of hypertensive patients
with diabetes is also expected to increase, the opportunities
for clinicians to use an ARB in conjunction with an anti-
diabetic medication are expected to grow. Therefore, verify-
ing the effectiveness of this combination therapy in patients
with hypertension and diabetes is of clinical significance.
However, the utility of such combination therapy from the
viewpoint of their anti-inflammatory effects has not been
clarified.
In this study, we administered as an ARB candesartan,
which is the only sartan approved for use in chronic heart
failure patients in Japan, and pioglitazone, an anti-diabetic
medicine that improves insulin resistance, for 6 months to
hypertensive patients with T2DM of long duration but
without a history of cardiovascular events. We evaluated
whether there was improvement in the serum inflamma-
tory parameters of high-molecular-weight adiponectin
(HMW-ADN), plasminogen activator inhibitor-1 (PAI-1),highly sensitive C-reactive protein (Hs-CRP), vascular cell
adhesion molecule-1 (VCAM-1), and urinary-8-hydroxy-
deoxyguanosine (U-8-OHdG). We then analyzed the rela-
tionship between the degree of lowering of HbA1c and
blood pressure and changes in inflammatory factors. Fur-
thermore, the relationship between pulse pressure and the
degree of lowering of HbA1c and changes in inflammatory
factors was analyzed. Finally, we analyzed predictors of
which patients would benefit from co-administration of




In this prospective study, patients were targeted for enroll-
ment among hypertensive patients with T2DM (defined
according to ADA criteria [11] or the use of anti-diabetic
agents) who regularly attended the Jikei University School
of Medicine affiliated hospital for treatment. We enrolled
41 patients (34 males and 7 females, 25–75 years old, aver-
age 60 years) who had hypertension (defined as diastolic
blood pressure [DBP] ≧80 mmHg or systolic blood pres-
sure [SBP] ≧130 mmHg, average 141/86) or who were
taking anti-hypertensive agents (Table 1). Patients with
secondary hypertension were excluded, as were patients
with impaired liver function defined by plasma amino-
transferase (or aspartate aminotransferase) >39 mUml
(normal values: 11–39 mUml) and alanine aminotrans-
ferase >34 mUml (normal values: 11–34 mUml) or im-
paired kidney function (defined as serum creatinine
level >1.3 mg/100 ml (normal values: 0.6–1.3 mg/100 ml).
Also excluded were those with unstable cardiovascular
conditions (e.g., New York Heart Association class I–IV
congestive heart failure or a history of myocardial infarc-
tion or stroke) or who had a cerebrovascular incident
within 6 months of study enrollment. Women who were
pregnant, lactating or who might become pregnant due to
inadequate contraceptive precautions were also excluded.
Patients with known contraindications or intolerance to
candesartan or pioglitazone were also excluded. Patients
were simultaneously administered 12 mg candesartan and
15 mg pioglitazone daily for a duration of 6 months. If
at the beginning of the study patients were taking an
ARB or ACE-I, that drug was replaced with 12 mg
candesartan. Anti-hypertensive and anti-diabetic agents
were not changed during this study. The study protocol
Table 1 Baseline data on study subjects
N 41
Sex (M/F) 34 (87.2%)
Age (year) 59.74 (1.29)
BW (kg) 73.24 (2.50)
BMI (kg/m2) 26.40 (0.71)
Blood pressure (SBP/DBP)(mmHg) 141(2.14)/85.5(1.57) (1.57)
Duration (year) 16.32 (1.67)
Laboratory data
HbA1c (%) 8.32 (1.23)
FPG (mol/l) 9.72 (0.49)
LDL-C (mg/dl) 108.8 (3.41)
HDL-C (mg/dl) 48.8 (2.13)
Triglycerides (mg/dl) 148.0 (11.72)







F, female; M, male, BMI, Body-mass index; DBP, diastolic blood pressure; SBP,
systolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated
hemoglobin; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low density
lipoprotein-cholesterol; OHA, oral hypoglycemic agent. Data are expressed as
means (SEM) or n and %.
Table 2 Patient data at baseline and after 6-mo study
period
N 41 39
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University School of Medicine and conducted in accord-
ance with the Declaration of Helsinki and its amend-
ments. After a full explanation of the study, all patients
gave written informed consent.Dropped out N/A 2
BW(kg) 73.24 (2.50) 74.8 (2.29
BMI(kg/m2) 26.40 (0.71) 26.95 (0.69)
Blood pressure(SBP/DBP)
(mmHg)
141 (2.14)/ 133 (2.04)*/
85.5 (1.57) 79.3 (1.51)
Laboratory data
HbA1c (%) 8.32 (0.20) 7.48 (0.17)*
FPG (mol/l) 9.72 (0.49) 8.17 (0.37)*
HMW-ADN (μg/ml) 4.50 (0.60) 7.99 (0.71)*
PAl-1 (mg/dl) 32.7 (2.60) 24.1 (1.89)*
VCAM-1 (mg/dl) 698.9 (27.9) 680.6 (30.15)
U-8-OHdg (ng/mg cr) 11.7 (0.62) 11.7 (0.44)
Hs-CRP (mg/dl) 0.27 (0.05) 0.19 (0.04)
BMI, Body-mass index; DBP, diastolic blood pressure; SBP, systolic blood
pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HMW-
ADN, high molecular weight-adiponectin; Hs-CRP, high sensitivity-Creactive
protein; PAI-1, plasminogen activator inhibitor-1; U-8-OHdg, urinary-
8-hydroxydeoxygnosine; VCAM-1, vascular cell adhesion molecule-1. Data are
expressed as means (sem). or n and %. *P<0.01.Baseline assessment of participants
Before starting the study, all patients underwent an initial
screening assessment that included a medical history and
physical examination. We evaluated patients at the start
of the study to establish baseline values, then again after
the 6th month of treatment. Parameters examined were
as follows: body weight, body mass index (BMI), SBP,
DBP, HbA1c, fasting plasma glucose (FPG), HMW-ADN,
PAI-1, Hs-CRP, VCAM-1, and U-8-OHdG. To evaluate
tolerability of candesartan and pioglitazone, all adverse
events were recorded. All plasmatic parameters were
measured after a 12-h overnight fast. In all cases, ven-
ous blood samples were taken between 800 and 900 h.
We used plasma obtained by the addition of Na2-EDTA
(1 mgml_1) and centrifuged at 3000 g for 15 min at 4°C.
All measurements were performed in a central laboratory.
BMI was calculated as weight (kg) divided by the square
of height (m). Height and weight were determined using astandard scale (SYSTEM 502, TANITA, Tokyo, Japan).
Blood pressure measurements were obtained from the
right arm while patients were in a seated position
using a standard sphygmomanometer (ADVANCE BP-
203RVIIIC/D, OMRON colin, Tokyo, Japan) (Korotkoff I
and V) with an appropriately-sized cuff. Furthermore, the
same investigator measured patients’ blood pressure at
each visit, always in the morning and after the patient had
rested for at least 10 min in a quiet room. Three succes-
sive blood pressure readings were obtained at 1-min inter-
vals, and the mean of the three readings was calculated.
HbA1c level was measured by high-performance liquid
chromatography (HPLC) (HLC723-G9, TOSOH, Tokyo,
Japan), with intra- and interassay coefficients of variation
(CsV) of 1%. Plasma glucose was assayed by the glucose-
oxidase method (GA08II, A&T, Yokohama, Japan) with
intra- and inter-assay CsV of 0.8%. Plasma HMW-ADN
level was determined using a chemiluminescent enzyme
immunoassay (CLEIA) (Fuji Rebio, Tokyo, Japan). Plasma
VCAM-1 level (normal values 277–836 ng/ml) was deter-
mined using an enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Inc., Minneapolis, MN, USA).
Plasma PAI-1 levels (normal values ≤50 ng/ml) were
determined using a latex photometric immunoassay
(LPIA) (Mitsubishi Chemical Medience, Tokyo, Japan).
The U-8-OHdG level (normal values l: 6.1-16.3 ng/mg·cr)
was measured using HPLC (Mitsubishi Chemical
Medience, Tokyo, Japan). Plasma Hs-CRP level (normal





















Figure 1 Changes from baseline of blood pressure parameters
after treatment. Systolic blood pressure (SBP) and diastolic blood
pressure (DPB). *P<0.01 vs. Pre. Error bars indicate SEM for SBP and
for DBP.
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Statistical analysis
Statistical analysis of data was performed using the
Statistical Package for Social Sciences software, version
19.0 (SPSS, Chicago, IL, USA). Data are presented as
the mean ± s.e. For all statistical analyses, P<0.05 was
considered statistically significant.
Results
Characteristics of study sample
Of the 41 patients who were enrolled in the study, 39
completed the study. The reason for premature with-
drawal was lost-to-follow-up. Characteristics of the patient
population upon entering the study and the antidiabetic
treatments taken before and during the study are shown
in Table 1. Patient data at baseline and after the 6th month
of the study are shown in Table 2. Significant improve-















Figure 2 Changes from baseline of glucose parameters after treatme
Error bars indicate SEM for HbA1c and for FPG.and DBP after 6 months *P<0.01, Table 2 and Figure 1).
HbA1c and FPG values were significantly improved from
baseline after the 6-month treatment period *P<0.01,
Table 2 and Figure 2).
Furthermore, significant improvements in baseline values
for HMW-ADN and PAI-1 were recorded in all patients
after 6 months of treatment (*P<0.05, **P<0.01, respect-
ively). VCAM-1, U-8-OHdG, and Hs-CRP values did not
decrease from baseline after 6 months of candesartan with
pioglitazone treatment (Figure 3).
Correlations
Stepwise multilinear regression analysis was performed
to establish which factors could best predict changes in
patients’ inflammatory factors. Co-administration of
candesartan with pioglitazone improved inflammatory
parameters (HMW-ADN and PAI-1) in hypertensive pa-
tients with T2DM of long duration independent of blood
pressure changes. In addition, the following positive corre-
lations with changes in HbA1c (⊿HbA1c) were revealed:
⊿HbA1c vs.⊿HMW-ADN (r=−0.382, P=0.018, Figure 4A)
and ⊿HbA1c vs. ⊿PAI-1(r=0.404, P=0.015, Figure 4B).
Results of other correlation analyses did not show patterns
of associations with regard to ⊿HbA1c with ⊿VCAM-1,
⊿8-OHdG, and ⊿Hs-CRP (Additional file 1: Figure S1).
There were no correlations between changes in SBP
and DBP (⊿SBP and ⊿DBP) and the following parameters:
⊿SBP vs. ⊿HMW-ADN, ⊿SBP vs. ⊿PAI-1, ⊿DBP vs.
⊿HMW-ADN, and ⊿DBP vs. ⊿PAI-1 (Figure 5A, B, C,
and D, respectively). And there were no correlations
between ⊿SBP, ⊿DBP and the following parameters: ⊿SBP
vs. ⊿VCAM-1, ⊿SBP vs. ⊿U-8-OHdG, ⊿SBP vs.
⊿Hs-CRP, ⊿DBP vs. ⊿VCAM-1, ⊿DBP vs. ⊿U-8-OHdG,
⊿DBP vs.⊿Hs-CRP (Additional file 2: Figure S2, Additional
file 3: Figure S3). Furthermore, correlation analyses
indicated that no associations existed between ⊿SBP and










































































































Figure 3 Changes from baseline of inflammatory parameters after treatment. HMW-ADN, high molecular weight adiponectin; Hs-CRP,
highly sensitive C-reactive protein; PAI-1, plasminogen activator inhibitor-1; U-8-OHdG, urinary 8-hydroxydeoxyguanosine; VCAM-1, vascular cell
adhesion molecule-1. Error bars indicate SEM for HMW-AND. *P<0.05 vs Pre. **P<0.01 *P=0.002 vs Pre. Error bars indicate SEM for PAI-1.
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In this prospective trial of patients with hypertension
and T2DM, we observed that co-administration of
candesartan with pioglitazone had beneficial effects
with regard to hypertension, inflammation, and adi-





















Figure 4 Metabolic and inflammatory factors vs. ⊿HbA1c. (A). ⊿HMW
P=0.015.receiving treatment with both agents experienced a
significant improvement in blood pressure, HbA1c,
HMW-ADN, and PAI-1. Furthermore, we analyzed
predictive factors in patients who received the





































































































Figure 5 Metabolic and inflammatory factors vs. ⊿SBP and ⊿DBP. (A). ⊿HMW-ADN vs. ⊿SBP: r=−0.090, P=0.630; (B). ⊿PAI-1 vs. ⊿SBP:
r=0.241, P=0.207; (C). ⊿HMW-ADN vs. ⊿DBP: r=−0.382, P=0.165; (D). ⊿PAI-1 vs. ⊿DBP: r=0.210, P=0.285.
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Both candesartan and pioglitazone were clinically proven
to provide direct cardiovascular protection through pleio-
tropic effects [12-16] not only in basic studies. Further-


















Figure 6 Blood pressure vs. ⊿HbA1c. (A). ⊿SBP: r= 0.151, P=0.410; (B). ⊿oxidative stress in tissues have been the center of attention
as the pleiotropic action of both drugs. The combination
of candesartan and pioglitazone was more effective than
candesartan monotherapy in pigs and rats with cardiovas-

















Table 3 Multivariate regression analysis of variables for
⊿HbA1c
β P value
Pulse pressure 0.492 0.012*
Age 0.178 0.298(NS)
Body mass index -0.084 0.653(NS)
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protective effects on renal fibrosis in an experimental
mouse model, suggesting that their use in combination
would be an effective treatment for chronic kidney
disease [19]. Moreover, in patients with T2DM in whom
prior hypoglycemic therapies failed, pioglitazone co-
administration improved blood lipid and glycemic profiles,
thus decreasing the proportion of patients with a high
microvascular or macrovascular risk [20]. Therefore, we
retrospectively analyzed the effects of co-administration
therapy compared to the use of candesartan monotherapy
on HMW-ADN and PAI-1, which we addressed previ-
ously [4]. After adjustment for age, BMI, HbA1c and
blood pressure values, the co-administration arm com-
pared to the candesartan administration only arm had a
significant improvement in ⊿HMW-ADN and a tendency
toward improvement in ⊿PAI-1 (%) (Additional file 4:
Figure S4).
That there has been an increase in hypertensive pa-
tients with T2DM supports the clinical importance of
this research. Our data suggest that this therapy was ef-
fective from the viewpoint of inflammatory parameters
(HMW-ADN and PAI-1) for hypertensive patients with
T2DM with a cardiovascular risk. However, these data
were not investigated at the same time for the same pur-
pose, which might be considered a limitation of this
study. Large-scale prospective multi-arm studies are















Figure 7 Single correlation analysis of pulse pressure and degree of lCorrelation between ⊿HbA1c and inflammatory factors
⊿HMW-ADN and ⊿PAI-1
A positive correlation was observed in ⊿HMW-ADN and
⊿PAI-1 and changes in HbA1c (Figure 4A, B). Our data
might be thought to indicate that the improvement in
HMW-ADN·PAI-1 with plasma glucose (HbA1c) created
a virtuous circle. Did the improvement in plasma glucose
cause the improvement in inflammatory parameters or
was the opposite correct? The truth is unknown. But our
results showed close relationships between inflammation
and blood glucose levels. Pioglitazone has a dose–response
effect on insulin sensitivity and insulin secretion in T2DM
[21-24]. We are inclined to the opinion that if these
patients would take pioglitazone 30–45 mg daily, further
improvement in the inflammatory parameters in addition
to HbA1c would be achieved by a virtuous circle.
Correlation between ⊿SBP,⊿DBP and inflammatory
factors ⊿HMW-ADN and ⊿PAI-1
⊿SBP and ⊿DBP correlation analyses did not indicate
patterns of associations with these parameters (Figure 5A,
B, C, D). These results might indicate that candesartan im-
proved these parameters directly and not through changes
in blood pressure or that it had lesser effects in patients
with diabetes mellitus of a long duration.
Correlation between ⊿HbA1c and pulse pressure values
at baseline
Interestingly, by correlation analysis we observed a sig-
nificant correlation between the degree of lowering of
HbA1c (⊿HbA1c) and pulse pressure values at baseline.
Furthermore, multiple regression analysis showed that
pulse pressure was independent of age and BMI (Table 3
and Figure 7). In summary, these data suggest that pulse
pressure values at baseline can become a key predictive
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owering of HbA1c. r=0.370, P=0.034.
Suzuki et al. Cardiovascular Diabetology 2013, 12:71 Page 8 of 9
http://www.cardiab.com/content/12/1/71pulse pressure is an index parameter of arteriosclerosis
[25,26]. In brief, our data suggest that the patients in our
study who did not have advanced atherosclerosis were
those who could benefit most from this treatment. These
results are unique. We think that there is an important rela-
tionship between blood pressure and plasma glucose, and
the reason for this should be examined in the future.Benefits and risks of pioglitazone
Among our study patients, we did not observe increases
in body weight, exacerbation of heart failure, and the de-
velopment of bladder cancer after 6 months of treatment.
In France, analysis revealed a significant association be-
tween pioglitazone and bladder cancer in men [27]. But in
Asia, two reports showed no relation of thiazolidinediones
with bladder cancer. [28,29]. Cariou et al. noted that the
thiazolidinediones, mainly pioglitazone, remain effective
and useful anti-diabetic drugs with a unique insulin-
sensitizing action. This therapeutic option must be vali-
dated by a decrease in HbA1c and the lack of serious
adverse events [30]. Also, with regard to cardiovascular
outcomes, pioglitazone is useful for patients with cardio-
vascular and microvascular risks [12,13,20]. Therefore,
pioglitazone has benefits in hypertensive patients with
T2DM who are at high risk for cardiovascular disease.Study limitations
This was a pilot study. It was a single group pre-post
study of a small number of patients with unbalanced dis-
tribution between men and women. Co-administration
therapy for 6 months was less effective with regard to
VCAM-1, U-8-OHdG, and Hs-CRP. The precise reason
is unknown. Results of larger clinical trials evaluating
the anti-inflammatory effects of the co-administration of
candesartan with pioglitazone are awaited.Conclusion
In conclusion, the simultaneous co-administration of
candesartan with pioglitazone improved inflammatory
parameters (HMW-ADN and PAI-1), and improve-
ments in inflammatory parameters were correlated with
⊿HbA1c. Pulse pressure values at baseline can become
a key predictive factor for changes in patients’ HbA1c.
The co-administration of candesartan with pioglitazone
could be an effective therapeutic strategy for treating
hypertensive patients with T2DM.Additional files
Additional file 1: Figure S1. Inflammatory factors vs. ⊿HbA1c.
(A). ⊿VCAM-1 vs. ⊿HbA1c: r=0.318, P=0.058; (B). ⊿8-OHdG vs. ⊿HbA1c:
r= 0.215, P=.201; (C). ⊿Hs-CRP vs. ⊿HbA1c; r= 0.239; P=0.203.Additional file 2: Figure S2. Inflammatory factors vs. ⊿SBP.
(A). ⊿VCAM-1 vs. ⊿SBP: r=−0.085, P=0.642; (B). ⊿U-8-OHdG vs. ⊿SBP:
r=0.043, P=0.823; (C). ⊿Hs-CRP vs. ⊿SBP: r=−0.278, P=0.170.
Additional file 3: Figure S3. Inflammatory factors vs. ⊿DBP.
(A). ⊿VCAM-1 vs. ⊿DBP: r=−0.066, P=0.726; (B). ⊿U-8-OHdG vs. ⊿DBP:
r=−0.132, P=0.494; (C). ⊿Hs-CRP vs. ⊿DBP: r=−0.286, P=0.156.
Additional file 4: Figure S4. Co-administration vs. single candesartan.
After adjusted HbA1c in both patients, co-administration arm compared to
candesartan administration only arm significantly improved in ⊿HMW-ADN
and ⊿PAI-1 (%). *P<0.05 vs Candesartan (Can). Error bars indicate SEM for
Can and for Candesartan + Pioglitazone (Can + Pio).
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